List of Biologics Companies in Norway - 11

APIM Therapeutics is a venture capital financed Norwegian biotech company focusing on the development of novel treatments in the fields of oncology and inflammation. Our lead drug, ATX-101, is a first-in-class peptide drug candidate targeting a novel therapeutic intervention point involved in cellular stress defense mechanisms. ATX-101 is currently being tested in a phase I study in patients with advanced solid tumors.

Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on the unique properties of bioactive marine compounds. The company’s pharmaceutical business is developing a novel oral treatment for mild-to-moderate psoriasis, a large global market with significant unmet medical need. Arctic Bioscience will offer convenient and cost-efficient pharmaceutical treatment extracted from a natural raw material (herring roe). The nutraceutical business has proven traction in the premium Omega 3 market with global expansion potential in B2C and B2B channels. To support its long-term growth strategy, Arctic Bioscience is integrating its value chain and planning a state-of-the-art manufacturing facility with a proprietary production process to enable large-scale high-quality production. Based in Ørsta on the West Coast of Norway with access to locally sourced herring roe raw material and led by a team with 30+ years of marine extracts experience, Arctic Bioscience is on a mission to empower healthy lives.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.

Cytovation is a clinical-stage immuno-oncology biotech focused on the development of CyPep-1, a first-in-class tumor membrane immunotherapy for the treatment of various diseases, including benign tumors and malignant cancers.

Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lead compound LTX-315 provides access to antigens by using the patient’s own tumor as source of antigens and turns cold tumors hot. Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.

We are a leading technology platform that unlocks unlimited possibilities for the future of medicine through our intelligent modular design and tailored hyper targeting.

PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities. The company’s lead programme fimaVACC aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAC programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For further information, please visit: www.pcibiotech.com Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo PCI Biotech was established 2000 and is since June 2008 listed on the Oslo Børs. The company is headquartered in Oslo, Norway.

Thor Medical's primary market is to supply alpha emitters to suppliers and developers of innovative drugs targeting indications with high unmet medical needs, including any medical products and equipment. Going forward, the main business focus will be to refine the production technology, secure customer qualification and commitments, mature the manufacturing concept, and secure regulatory approvals and permits for industrialization.

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com